These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

201 related articles for article (PubMed ID: 22078241)

  • 21. Scientific rationale and study design of the individualized dosing efficacy vs flat dosing to assess optimal pegylated interferon therapy (IDEAL) trial: determining optimal dosing in patients with genotype 1 chronic hepatitis C.
    McHutchison J; Sulkowski M
    J Viral Hepat; 2008 Jul; 15(7):475-81. PubMed ID: 18363672
    [TBL] [Abstract][Full Text] [Related]  

  • 22. High rates of sustained virological response in hepatitis C virus-infected injection drug users receiving directly observed therapy with peginterferon alpha-2a (40KD) (PEGASYS) and once-daily ribavirin.
    Waizmann M; Ackermann G
    J Subst Abuse Treat; 2010 Jun; 38(4):338-45. PubMed ID: 20362408
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Retreatment of hepatitis C patients with pegylated interferon combined with ribavirin in non-responders to interferon plus ribavirin. Is it different in real life?
    Gonçales FL; Moma CA; Vigani AG; Angerami AF; Gonçales ES; Tozzo R; Pavan MH; Gonçales NS
    BMC Infect Dis; 2010 Jul; 10():212. PubMed ID: 20646277
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A randomized controlled trial adding fluvastatin to peginterferon and ribavirin for naïve genotype 1 hepatitis C patients.
    Bader T; Hughes LD; Fazili J; Frost B; Dunnam M; Gonterman A; Madhoun M; Aston CE
    J Viral Hepat; 2013 Sep; 20(9):622-7. PubMed ID: 23910646
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Directly observed antiretroviral therapy in substance abusers receiving methadone maintenance therapy does not cause increased drug resistance.
    Brust JC; Litwin AH; Berg KM; Li X; Heo M; Arnsten JH
    AIDS Res Hum Retroviruses; 2011 May; 27(5):535-41. PubMed ID: 20854173
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Short versus standard treatment with pegylated interferon alfa-2A plus ribavirin in patients with hepatitis C virus genotype 2 or 3: the cleo trial.
    Mecenate F; Pellicelli AM; Barbaro G; Romano M; Barlattani A; Mazzoni E; Bonaventura ME; Nosotti L; Arcuri P; Picardi A; Barbarini G; D'Ambrosio C; Paffetti A; Andreoli A; Soccorsi F;
    BMC Gastroenterol; 2010 Feb; 10():21. PubMed ID: 20170514
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Concurrent group treatment for hepatitis C: implementation and outcomes in a methadone maintenance treatment program.
    Stein MR; Soloway IJ; Jefferson KS; Roose RJ; Arnsten JH; Litwin AH
    J Subst Abuse Treat; 2012 Dec; 43(4):424-32. PubMed ID: 23036920
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Lack of sustained improvement in adherence or viral load following a directly observed antiretroviral therapy intervention.
    Berg KM; Litwin AH; Li X; Heo M; Arnsten JH
    Clin Infect Dis; 2011 Nov; 53(9):936-43. PubMed ID: 21890753
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Peginterferon alfa-2a and ribavirin for 16 or 24 weeks in HCV genotype 2 or 3.
    Shiffman ML; Suter F; Bacon BR; Nelson D; Harley H; Solá R; Shafran SD; Barange K; Lin A; Soman A; Zeuzem S;
    N Engl J Med; 2007 Jul; 357(2):124-34. PubMed ID: 17625124
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Low Efficacy of Pegylated Interferon plus Ribavirin plus Nitazoxanide for HCV Genotype 4 and HIV Coinfection.
    Macías J; López-Cortés LF; Téllez F; Recio E; Ojeda-Burgos G; Ríos MJ; Rivero-Juárez A; Delgado M; Rivas-Jeremías ; Pineda JA
    PLoS One; 2015; 10(12):e0143492. PubMed ID: 26640956
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Extended peginterferon plus ribavirin treatment for 72 weeks versus standard peginterferon plus ribavirin treatment for 48 weeks in chronic hepatitis C genotype 1 infected slow-responder adult patients.
    Katz LH; Goldvaser H; Gafter-Gvili A; Tur-Kaspa R
    Cochrane Database Syst Rev; 2012 Sep; 2012(9):CD008516. PubMed ID: 22972122
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Peginterferon alfa-2a plus ribavirin for HIV-HCV genotype 1 coinfected patients: a randomized international trial.
    Rodriguez-Torres M; Slim J; Bhatti L; Sterling R; Sulkowski M; Hassanein T; Serrão R; Sola R; Bertasso A; Passe And S; Stancic S
    HIV Clin Trials; 2012; 13(3):142-52. PubMed ID: 22592094
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Role of individualization of hepatitis C virus (HCV) therapy duration in HIV/HCV-coinfected individuals.
    Hopkins S; Lambourne J; Farrell G; McCullagh L; Hennessy M; Clarke S; Mulcahy F; Bergin C
    HIV Med; 2006 May; 7(4):248-54. PubMed ID: 16630037
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Adherence to treatment for recently acquired hepatitis C virus (HCV) infection among injecting drug users.
    Grebely J; Matthews GV; Hellard M; Shaw D; van Beek I; Petoumenos K; Alavi M; Yeung B; Haber PS; Lloyd AR; Kaldor JM; Dore GJ;
    J Hepatol; 2011 Jul; 55(1):76-85. PubMed ID: 21145855
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Induction pegylated interferon alfa-2a and high dose ribavirin do not increase SVR in heavy patients with HCV genotype 1 and high viral loads.
    Reddy KR; Shiffman ML; Rodriguez-Torres M; Cheinquer H; Abdurakhmanov D; Bakulin I; Morozov V; Silva GF; Geyvandova N; Stanciu C; Rabbia M; McKenna M; Thommes JA; Harrison SA;
    Gastroenterology; 2010 Dec; 139(6):1972-83. PubMed ID: 20816836
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Efficacy of combined antiviral therapy with pegylated interferon alpha-2a and ribavirin for chronic hepatitis C infection in intravenous drug users].
    Ruzić M; Milotka F; Klasnja B; Pobor M; Svarc D; Jovelic A; Fabri I
    Srp Arh Celok Lek; 2010; 138(1-2):43-9. PubMed ID: 20425908
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Peginterferon alfa-2a and ribavirin for 24 weeks in hepatitis C type 1 and 4 patients with rapid virological response.
    Ferenci P; Laferl H; Scherzer TM; Gschwantler M; Maieron A; Brunner H; Stauber R; Bischof M; Bauer B; Datz C; Löschenberger K; Formann E; Staufer K; Steindl-Munda P;
    Gastroenterology; 2008 Aug; 135(2):451-8. PubMed ID: 18503773
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Sustained Virologic Response to a Dual Peginterferon alfa-2a and Ribavirin in Treating Chronic hepatitis C Infection: A Retrospective Cohort Study.
    Naing C; Sitt T; Aung AT; Aung K
    Medicine (Baltimore); 2015 Jul; 94(30):e1234. PubMed ID: 26222859
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Pegylated interferon-α2a with or without low-dose ribavirin for treatment-naive patients with hepatitis C virus genotype 1 receiving hemodialysis: a randomized trial.
    Liu CH; Huang CF; Liu CJ; Dai CY; Liang CC; Huang JF; Hung PH; Tsai HB; Tsai MK; Chen SI; Lin JW; Yang SS; Su TH; Yang HC; Chen PJ; Chen DS; Chuang WL; Yu ML; Kao JH
    Ann Intern Med; 2013 Dec; 159(11):729-38. PubMed ID: 24297189
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Hepatitis C treatment of opioid dependants receiving maintenance treatment: results of a Norwegian pilot study.
    Krook AL; Stokka D; Heger B; Nygaard E
    Eur Addict Res; 2007; 13(4):216-21. PubMed ID: 17851243
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.